In vitro antibacterial activity of a new 1-oxa cephalosporin compound. by Downs, J. T. & Andriole, V. T.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 53 (1980), 149-159
In Vitro Antibacterial Activity of a
New 1-Oxa Cephalosporin Compound
JAMES T. DOWNS AND VINCENT T. ANDRIOLE
Department ofInternal Medicine, Yale University School ofMedicine,
New Haven, Connecticut
Received November 28, 1979
The in vitro activity of a unique new 1-oxa cephalosporin beta-lactam antibiotic (LY 127935)
was tested against clinical isolates of gram-positive and gram-negative bacteria and compared
with the activities of cefoxitin, cefamandole, cephalothin, clindamycin, amikacin, tobramycin,
gentamicin, ticarcillin, and carbenicillin. The new compound was observed to have a broad
spectrum of antibacterial activity which far exceeded the activity of older cephalosporins
against aerobic gram-negative enteric bacilli. This new compound was the most active drug
tested against Klebsiella, Serratia, Enterobacter, indole-negative and positive Proteus species,
and E. coli. Against clinical isolates of Pseudomonas species the new compound was more
active than cefoxitin, cefamandole, cephalothin, and clindamycin, comparable to ticarcillinand
carbenicillin, and less active than gentamicin, tobramycin, and amikacin. Yet, most of the
Pseudomonas isolates were inhibited by 16 ug/ml of the new compound. Against both beta-
lactamase and non beta-lactamase producing Staphylococcus aureus isolates, the new 1-oxa
compound was less active than the older cephalosporins ofwhich cephalothin and cefamandole
were the most effective. The 1-oxa compound had no appreciable activity against isolates of
Streptococcusfaecalis. Activity ofall fourcephalosporins studied was decreased in the presence
of an increased inoculum of Enterobacteriaceae in trypticase soy and Mueller-Hinton broth.
The activity of the new compound against Pseudomonas species was also decreased by an
increased inoculum in Mueller-Hinton but not in trypticase soy broth. These results indicate
that this new l-oxa compound may have great promise as a broad spectrum antibiotic and may
warrant controlled clinical trials in man.
Recently, a number of new cephalosporins have been introduced which have
expanded the antibacterial spectrum of this class of antimicrobial agents [1,2]. One
of these compounds, (6R, 7R)-7{(Carboxy(4-hydroxyphenyl) acetyl) amino]-7-
methoxy-3-[(1-methyl-iH-tetrazol-5-yl) thio) methyl]-8-oxo-5 oxa-I azabicyclo-
[4.2.0] oct-2-ene-2 carboxylic acid (LY 127935), is a new beta lactam antibiotic.
Structurally, this compound contains a conventional cephem nucleus in which
oxygen is substituted in place of sulfur in the six-membered ring [3].
The purpose of this study was to characterize more thoroughly the in vitro activ-
ity of this new antibiotic against a wide variety of gram-negative and gram-positive
organisms isolated from patients and to compare their activity to the antimicrobial
activity of agents currently in clinical use. Specifically, the in vitro activity of LY
127935 was compared to that of cefoxitin, cephalothin, cefamandole, carbenicillin,
ticarcillin, gentamicin, tobramycin, amikacin, and clindamycin.
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MATERIALS AND METHODS
Antibiotics
Ten antibacterial agents were tested and were kindly supplied as laboratory
standards by their manufacturers. Gentamicin was supplied by Schering Corpora-
tion, Bloomfield, NJ; tobramycin, cefamandole, keflin, LY 127935 were forwarded
from Eli Lilly and Company, Indianapolis, IN; amikacin came from Bristol Labora-
tories, Syracuse, NY; cefoxitin was supplied by Merck, Sharpe and Dohme, West
Point, PA; ticarcillin was supplied by Beecham Laboratories, Bristol, TN; carbenicil-
lin came from Roerig, New York, NY; and clindamycin was supplied by Upjohn
Company, Kalamazoo, MI. Dilutions of the antibiotic were prepared fresh in sterile
growth medium and used the same day.
Bacterial Strains
Fifteen strains each of Pseudomonas aeruginosa, Klebsiellapneumoniae, Escheri-
chia coli, Serratia marscescens, Enterobacter species, indole positive Proteus, indole
negative Proteus, penicillin sensitive Staphylococcus aureus, penicillin resistant
Staphylococcus aureus, and Group D Streptococci were clinical isolates used in this
study. These strains were obtained from patients hospitalized within the past year at
Yale-New Haven Hospital and the West Haven Veterans Administration Hospital.
All fifteen strains of penicillin resistant S. aureus showed minimal inhibitory
concentrations (MIC) of penicillin (Eli Lilly and Co., Indianapolis, IN) equal to or
greater than 512 ug/ml as determined with the microtiter method outlined below.
Penicillin sensitivity among S. aureus strains was defined by a zone ofinhibition ofat
least 29 mm around a 10 IU penicillin impregnated disc, using standard Kirby-Bauer
technique [4].
In Vitro Testing
For MICs, eleven twofold serial dilutions of each antimicrobial in trypticase soy
broth (TSB) (BBL, Inc., Cockeysville, MD) were prepared [5,6]. The highest
concentrations of each drug tested were as follows: gentamicin and tobramycin, 32
ug/ml; amikacin, cefoxitin, cephalothin, cefamandole, and LY 127935, 128 ug/ml;
ticarcillin and carbenicillin, 512 ug/ ml; clindamycin, 64 ug/ml. The dilutions ofeach
antimicrobial were applied to a 33/% x 41/4 inch microtiter plate containing 96 wells
arranged in eight rows of twelve wells each. Each well was loaded with 0.1 ml of the
appropriate drug dilution with a semi-automated pipettor (Dynatech, Inc., Alexan-
dria, VA). One column of wells on each plate contained drug-free medium as a
growth control. Each well was inoculated with 104 colony forming units (105 cfu/ml)
using an automated inoculator (Dynatech, Inc., Alexandria, VA). Eighteen-hour
broth cultures of each organism were adjusted by visible light colorimetry in order
that proper final inoculum densities were obtained. At the end of 18-24 hours'
incubation at 370C, duplicate rows for each strain were compared and MICs
recorded as the lowest concentration ofantibiotic which showed no visual turbidity.
Where duplicate rows differed by only one well, MICs were reported as the higher
concentration. Duplicates that differed by more than one well were repeated until
consistent results were obtained. Minimal bactericidal concentrations (MBC) were
determined by transferring an aliquot from each well of an MIC plate to trypticase
soy agar (TSA) (BBL, Inc., Cockeysville, MD) poured into single-well 3% x 41/4 inch
trays with the automated inoculating system previously described. The MBC was the
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concentration at which no colonial growth appeared after 24 hours of incubation at
370C.
Inoculum Density and Media Testing
In order to determine effects of varying inoculum cell density and media,
cephalothin, cefoxitin, cefamandole, and LY 127935 vs. all 150 organisms were
tested in the following combinations: (1) 1 x 107 cfu/ml in TSB; (2) 1 x 105 cfu/ml in
Mueller-Hinton broth (MHB); (3) 1 x 107 cfu/ml in MHB as well as with 1 x 105
cfu/ml in TSB as described above and MICs and MBCs were determined.
RESULTS
The comparative in vitro activities of the 1-oxa cephalosporin and other antimi-
crobical agents are shown in Table 1. Against Pseudomonas species the I-oxa
compound was more active than cefoxitin, cefamandole, cephalothin, and clindamy-
cin, was comparable in activity to ticarcillin and carbenicillin, but was less active than
the aminoglycosides, gentamicin, tobramycin, and amikacin. The I-oxa compound
was also more active than cefoxitin, cefamandole, cephalothin, clindamycin, ami-
kacin, tobramycin, gentamicin, ticarcillin, and carbenicillin against Klebsiella,
Serratia, Enterobacter, and both indole negative and positive Proteus species, as well
as E. coli. Furthermore, our results indicate that the I-oxa compound inhibited
members of the Enterobacteriaceae at lower concentrations than did the older
cephalosporin, cephalothin, or the newer ones, cefamandole and cefoxitin. In fact,
the new I-oxa cephalosporin compound was the most active agent tested against
Klebsiella, Serratia, Enterobacter, indole negative and positive Proteus species, and
E. coli. For example, the new compound inhibited 50 and 90 percent of: Klebsiella
species isolates at concentrations of 0.25 and 0.5 ug/ml, respectively; Serratia spe-
cies isolates at concentrations of 0.5 and 8 ug/ml respectively; Enterobacter
species isolates at concentrations of 0.25 and 4.0 ug/ml, respectively; indole nega-
tive Proteus species isolates at concentrations of less than 0.12 ug/ml; indole
positive Proteus species isolates at concentrations of less than 0.12 and 0.25 ug/ml,
respectively; and E. coli isolates at concentrations of less than 0.12 and 0.5 ug/ml,
respectively. No other antibiotic tested in this study demonstrated such a high degree
of in vitro activity against these bacterial isolates. However, the new compound was
less active than the aminoglycosides against Pseudomonas species isolates. For
example, 50 percent ofthe Pseudomonas isolates tested were inhibited by 16 ug/ml of
the new compound, a concentration comparable to carbenicillin, ticarcillin and
gentamicin, but more than the concentration oftobramycin (2.0 ug/ml) or amikacin
(4.0 ug/ml) required to inhibit the same number ofisolates. Similarly, 90 percent of
the Pseudomonas isolates were inhibited by the 1-oxa compound at a concentration
of 128 ug/ml or less, which was lower than the concentrations of all other antimic-
robial agents studied except for the aminoglycosides, and of these, tobramycin, at a
concentration of 2.0 ug/ml, was the most active.
Against non-beta lactamase producing isolates of Staphylococcus aureus the new
compound was less active than cefamandole, cephalothin, clindamycin, tobramycin,
and carbenicillin, and was comparable in activity to cefoxitin, amikacin, gentamicin,
and ticarcillin. In fact, cephalothin and cefamandole were the most active agents
against these staphylococcal isolates as well as against the beta-lactamase producing
isolates of Staphylococcus aureus which were tested in this study. The new com-
pound was more active against these beta-lactamase producing staphylococcal
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TABLE I
Comparative In Vitro Activity of I-Oxa Cephalosporin and Other Antibiotics in
Trypticase Soy Broth with an Inoculum of I x 105 cfu/ml
Range of MIC 50% MIC 90% MIC
Organism (No. of strains) Drug (ug/ ml) (ug/ml) (ug/ml)
Pseudomonas sp. (15) Carbenicillin 16.0->512 32 >512
Ticarcillin 8.0-512 16 512
Gentamicin 1.0-8.0 8.0 8.0
Tobramycin 0.5-4.0 2.0 2.0
Amikacin 2.0-8.0 4.0 8.0
Clindamycin >64.0 >64 >64
Cephalothin >128 >128 >128
Cefamandole >128 >128 >128
Cefoxitin 128->128 >128 >128
I-Oxa 16.0-128 16 128
Klebsiella sp. (15)
Serratia sp. (15)
Enterobacter sp. (15)
Proteus sp. (15)
(Indole neg.)
Carbenicillin
Ticarcillin
Gentamicin
Tobramycin
Amikacin
Clindamycin
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Carbenicillin
Ticarcillin
Gentamicin
Tobramycin
Amikacin
Clindamycin
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Carbenicillin
Ticarcillin
Gentamicin
Tobramycin
Amikacin
Clindamycin
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Carbenicillin
Ticarcillin
Gentamicin
Tobramycin
Amikacin
Clindamycin
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
64.0->512
64.0->512
1.0-4.0
2.0->32
2.0-8.0
>64.0
2.0-8.0
0.5-4.0
4.0-16.0
<0.1-0.5
2.0->512
4.0->512
1.0->32
4.0->32
2.0-16.0
>64.0
16.0->128
4.0->128
16.0->128
0.2-32.0
2.0-128
<0.5-128
1.0-16.0
2.0-8.0
2.0-32.0
>64.0
8.0->128
1.0->128
32.0->128
<0.1-16.0
<0.5-5.2
<0.5-64
2.0-8.0
1.0-8.0
4.0-16.0
>64.0
2.0-128
0.5->128
4.0->128
<0.1-0.2
256
256
2.0
4.0
4.0
>64
2.0
1.0
4.0
0.25
4.0
4.0
4.0
8.0
8.0
>64
>128
32
32
0.5
4.0
4.0
2.0
4.0
4.0
>64
>128
4.0
>128
0.25
<0.5
1.0
4.0
4.0
4.0
>64
8.0
2.0
8.0
<0.12
>512
>512
4.0
4.0
8.0
>64
8.0
2.0
8.0
0.5
>512
>512
8.0
>32
16
>64
>128
64
128
8.0
32
64
4.0
8.0
16
>64
>128
>128
>128
4.0
8.0
32
8.0
8.0
16
>64
32
4.0
16
<0.12
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TABLE I
Continued
Organism (No. of strains)
Proteus sp. (15)
(Indole pos.)
S. aureus (15)
(Penicillin sensitive)
S. aureus (15)
(Penicillin resistant)
E. coli (15)
Enterococci (15)
Drug
Carbenicillin
Ticarcillin
Gentamicin
Tobramycin
Amikacin
Clindamycin
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Carbenicillin
Ticarcillin
Gentamicin
Tobramycin
Amikacin
Clindamycin
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Carbenicillin
Ticarcillin
Gentamicin
Tobramycin
Amikacin
Clindamycin
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Carbenicillin
Ticarcillin
Gentamicin
Tobramycin
Amikacin
Clindamycin
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Carbenicillin
Ticarcillin
Gentamicin
Tobramycin
Amikacin
Clindamycin
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Range of MIC
(ug/ml)
<0.5-16.0
<0.5-32.0
2.0-32.0
1.0-8.0
2.0-128
32.0->64.0
>128
1.0->128
4.0->128
<0.1-0.2
<-0.5-2.0
1.04.0
2.0-8.0
1.0-8.0
8.0-16.0
<0.06-0.12
<0.12-0.25
<0.12-0.25
4.0
<0.1-8.0
<0.54.0
2.0-8.0
0.25->32
0.5->32
2.0-128
<0.06->64
<0.12-0.25
0.25-4.0
1.0-2.0
4.0-8.0
2.0-8.0
2.0->512
2.0-8.0
4.0-8.0
2.0-8.0
>64.0
8.0-32
0.25-4.0
8.0-128
<0.1-1.0
16.0-32
32.0-64
32.0->32
32.0->32
64.0->128
8.0->64
8.0-32
8.0-32
>128
>128
50% MIC
(ug/ml)
1.0
<0.5
8.0
4.0
4.0
>64
>128
2.0
16
<0.12
<0.5
1.0
4.0
1.0
16
0.12
0.25
0.25
4.0
8.0
2.0
4.0
1.0
1.0
8.0
<0.06
0.25
0.25
1.0
4.0
4.0
4.0
4.0
4.0
8.0
>64
8.0
1.0
8.0
<0.12
16
32
>32
>32
>32
32
16
16
16
>128
90% MIC
(ug/ml)
8.0
16
32
8.0
16
>64
>128
>128
32
0.25
2.0
4.0
8.0
2.0
16
0.12
0.25
0.25
4.0
8.0
4.0
8.0
>32
>32
128
>64
0.25
0.5
2.0
8.0
8.0
8.0
4.0
8.0
8.0
>64
16
2.0
32
0.5
16
64
>32
>32
>32
>64
16
32
32
>128
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isolates than were the aminoglycosides and clindamycin, but was less active than the
other cephalosporins including cefoxitin. Furthermore, the I-oxa compound had
poor inhibitory activity against Streptococcus faecalis and was considerably less
active than the older cephalosporin antibiotics. Specifically, concentrations of 128
ug/ml of the new compound failed to inhibit the growth of any of the S. faecalis
isolates tested in this study.
Effect of inoculum size and growth medium. The effect of inoculum size on the
minimum inhibitory concentration of the cephalosporin compounds tested in this
study is shown in Table 2. In these experiments the inoculum size was increased a
hundredfold to 107 cfu per ml in trypticase soy broth (TSB). Higher concentrations of
each of the four cephalosporins were required to achieve inhibition of growth of the
larger inoculum of the Enterobacteriaceae isolates tested in this study although no
differences in MICs were observed against Pseudomonas species isolates. Similarly,
the in vitro activity of these four cephalosporin antibiotics was not significantly
increased by a hundredfold increase in inoculum size ofboth beta-lactamase and non
beta-lactamase producing strains of Staphylococcus aureus. The higher inoculum of
Streptococcusfaecalis isolates resulted in the loss of inhibitory activity of cefoxitin
and only slightly influenced the activity ofcefamandoleand cephalothin against these
bacterial strains. The new I-oxa compound had no detectable activity against the
isolates of Streptococcusfaecalis either at the lower or higher inoculum tested in this
study.
A comparison of the minimum inhibitory concentrations of these four cephalo-
sporins in Mueller-Hinton broth at both the lower (105 cfu per ml) and higher (107 cfu
per ml) inocula is shown in Tables 3 and 4. Again the activity of the new I-oxa
compound, as well as that ofcefoxitin, cefamandole, and cephalothin was decreased
against Klebsiella, Serratia, Enterobacter, indole negative and indole positive
Proteus species, and E. coli in the presence of the higher inoculum of 1 x 107 cfu per
ml in Mueller-Hinton broth as it was in trypticase soy broth (Tables 1 and 2).
However, in contrast to the results observed in trypticase soy broth the activity ofthe
I-oxa compound against Pseudomonas species isolates was decreased by the in-
creased inoculum in Mueller-Hinton broth (Tables 2 and 4). Furthermore, the
activity of all four cephalosporin antibiotics was also decreased by the increased
inoculum of non beta-lactamase producing Staphylococcus aureus isolates in
Mueller-Hinton broth but was not influenced by the larger inoculum of beta-
lactamase producing strains (Tables 3 and 4). This effect was not seen when these
isolates were tested with the higher inoculumin trypticase soy broth (Tables 1 and 2).
Also, the larger inoculum did not influence the activity of these cephalosporin
compounds against Streptococcus faecalis isolates when tested in Mueller-Hinton
broth (Tables 3 and 4), but the activity of cefoxitin against these isolates was
decreased when the lower inoculum was tested in Mueller-Hinton broth as compared
with trypticase soy broth (Tables 1 and 3).
The new 1-oxa compound was bactericidal for most of the species of organisms
studied and there was a minimal difference between MIC and MBC. Specifically, the
MBC of the I-oxa compound was only twofold higher than the MIC for both beta-
lactamase and non beta-lactamase producing Staphylococcus aureus isolates at
inocula of 105 and 107 but only in TSB. In fact, the new compound was more active
(lower MIC and MBC) against beta-lactamase producing strains of S. aureus in
MHB at inocula of either 105 or 107 organisms. Furthermore, except foj S.faecalis
isolates, MBCs were the same as MICs for 130/135 (96 percent) and 131/135 (97
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TABLE 2
Comparative In Vitro Activity of 1-Oxa Cephalosporin and Other Antibiotics in
Trypticase Soy Broth with an Inoculum of
Organism (No. of strains)
Pseudomonas sp. (15)
Drug
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Range of MIC
(ug/ml)
>128
>128
>128
8.0-128
lx107cfu/m
50% MIC
(ug/ml)
>128
>128
>128
16
90% MIC
(ug/ml)
>128
>128
>128
128
Klebsiella sp. (15)
Serratia sp. (15)
Enterobacter sp. (15)
Proteus sp. (15)
(Indole neg.)
Proteus sp. (15)
(Indole pos.)
S. aureus sp. (15)
(Penicillin sensitive)
S. aureus sp. (15)
(Penicillin resistant)
E. coli (15)
Enterococci (15)
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
1-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
1-Oxa
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
8.0-64
4.0-128
2.0->128
0.12->128
32.0->128
128->128
64.0->128
0.25->128
>128
128->128
128->128
0.5->128
8.0->128
2.0->128
4.0->128
4.0->128
>128
>128
4.0->128
0.2->128
<0.12-16
0.25-4.0
2.0-32
4.0-8.0
<0.12-16
<0.12-4
2.0-32
4.0->128
64.0->128
2.0->128
4.0->128
<0.12->128
8.0-64.0
16.0-32
>128
>128
16
16
8.0
1.0
>128
>128
128
8.0
>128
>128
>128
16.0
32
128
>128
>128
>128
>128
128
8.0
64
32
>128
>128
>128
>128
>128
>128
>128
>128
>128
>128
>128
>128
>128
>128
>128
>128
>128
8.0
0.25
0.5
2.0
8.0
4.0
2.0
4.0
8.0
<0.12
0.25
2.0
4.0
0.25
0.5
2.0
8.0
128 >128
2.0 >128
8.0 >128
1.0 >128
32
32
>128
>128
64
32
>128
>128
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TABLE 3
Comparative In Vitro Activity of l-Oxa Cephalosporin and Other Antibiotics in
Mueller-Hinton Broth with an Inoculum of 1 x 105 cfu/ml
Organism (No. of strains)
Pseudomonas sp. (15)
Klebsiella sp. (15)
Serratia sp. (15)
Enterobacter sp. (15)
Proteus sp. (15)
(Indole neg.)
Proteus sp. (15)
(Indole pos.)
S. aureus sp. (15)
(Penicillin sensitive)
S. aureus sp. (15)
(Penicillin resistant)
E. coli (15)
Enterococci (15)
Drug
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Range of MIC
(ug/mil)
>128
>128
>128
4.0-128
2.0-16
0.5-32
4.0->128
<0.1
8.0->128
1.0->128
4.0->128
<0.1-16.0
32->128
1.0->128
128->128
<0.1-8.0
2.0->128
0.5->128
4.0->128
<0.1
>128
0.5->128
4.0->128
<0.1
<0.1-8.0
<0.1-2.0
4.0-8.0
<0.2-16
4.0
<0.1-0.25
1.0-2.0
<0.1
4.0->128
0.5-64
2.0-32
<0.1-0.2
16.0-32
16.0-32
>128
>128
50% MIC
(ug/ml)
>128
>128
>128
8.0
4.0
1.0
4.0
<0.1
90% MIC
(ug/ml)
>128
>128
>128
128
16
4.0
64
<0.1
>128
16.0
16.0
0.25
>128
8.0
>128
<0.1
8.0
1.0
4.0
<0.1
>128
8.0
16.0
<0.1
0.25
0.25
4.0
8.0
4.0
<0.1
1.0
<10.I
8.0
1.0
4.0
<0.1
32
32
>128
>128
>128
>128
64
4.0
>128
>128
>128
2.0
>128
128
8.0
<0.1
128
128
64
<0.1
0.5
1.0
8.0
16
4.0
0.2
2.0
<0.1
32
4.0
32
0.25
32
32
>128
>128
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TABLE 4
Comparative in Vitro Activity of 1-Oxa Cephalosporn and Other Antibiotics in
Mueller-Hinton Borth with an Inoculum of I x 107 cfu/ml
Organism (No. of strains)
Pseudomonas sp. (15)
Klebsiella sp. (15)
Serratia sp. (15)
Enterobacter sp. (15)
Proteus sp. (15)
(Indole neg.)
Proteus sp. (15)
(Indole pos.)
S. aureus sp. (15)
(Penicillin sensitive)
S. aureus sp. (15)
(Penicillin resistant)
E. coli (15)
Enterococci (15)
Drug
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Cephalothin
Cefamandole
Cefoxitin
I-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Cephalothin
Cefamandole
Cefoxitin
l-Oxa
Range of MIC
(ug/ml)
>128
>128
>128
16.0->128
4.0-64
8.0->128
32->128
16.0->128
64->128
32->128
64-128
16.0->128
>128
>128
64->128
8.0-128
8.0->128
64->128
32->128
32-128
>128
64->128
16.0->128
0.2->128
<0.1->128
<0.1-32.0
2.0-64
8.0-16.0
4.0-8.0
0.25-1.0
1.0-2.0
<0.1-0.25
32->128
1.0->128
32-128
1.0->128
16.0-32
32-64
>128
>128
50% MIC
(ug/ml)
>128
>128
>128
128
16
64
64
32
>128
>128
64
128
>128
>128
>128
32
64
>128
64
64
>128
>128
64
32
0.25
0.5
16
8
4.0
0.5
2.0
<0.1
32
4.0
64
64
32
32
>128
>128
157
90% MIC
(ug/ml)
>128
>128
>128
>128
64
>128
>128
>128
>128
>128
128
>128
>128
>128
>128
128
>128
>128
64
128
>128
>128
>128
>128
32
32
64
16
8.0
1.0
2.0
0.25
>128
>128
128
>128
32
64
>128
>128DOWNS AND ANDRIOLE
percent) of isolates tested at an inoculum of 105 cfu per ml in either TSB or MHB,
respectively. Similarly, at the higher inoculum of 107 cfu per ml there was no
difference in MIC and MBC for 99/135 (73 percent) and 103/135 (76 percent) of
isolates tested in either TSB or MHB, respectively. For the remaining isolates, the
MBC was only twofold higher than the MIC.
DISCUSSION
The introduction of the "second generation" cephalosporins, cefamandole and
cefoxitin, resulted in a significant increase in the antibacterial spectrum of the older
"first generation" cephalosporins against many beta-lactamase-producing Enterobac-
teriaceae and Bacteroides isolates [3]. The new I-oxa cephalosporin compound
evaluated in the present study represents one of a new group of compounds which
can be referred to as "third generation" cephalosporins because these newer com-
pounds further enlarge the spectrum of antibacterial activity of the general class of
cephalosporin antibiotics to include isolates of Pseudomonas aeruginosa. The I-oxa
cephalosporin compound in the present report has in vitro activity similar to
another new "third generation" cephalosporin, cefotaxime (HR-756), against Enter-
obacteriaceae and has been shown to be twice as active as cefotaxime against
Pseudomonas aeruginosa and Bacteroidesfragilis subspeciesfragilis [2,3]. Although
we did not compare the in vitro activity of this new I-oxa compound to that of
cefotaxime, the results of the present study indicate that this new I-oxa cephalo-
sporin has a broad spectrum of activity against a variety ofclinical isolates including
gram-negative bacilli as well as staphylococci. It was the most active drug tested
against Klebsiella, Serratia, Enterobacter, indole negative and positive Proteus
species, and E. coli. Most of these isolates were inhibited by concentrations as low as
0.5 ug/ ml of this new compound. Furthermore, 50 percent of the clinical isolates of
Pseudomonas species were inhibited by concentrations of 16 ug/ ml ofthis compound
and, although less active than currently available aminoglycosides, this compound
has the potential to be clinically effective in the treatment of infections caused by
these bacteria.
The new compound was less active against both beta-lactamase and non beta-
lactamase producing staphylococcal isolates than the older cephalosporins, cepha-
lothin and cefamandole, which were the most effective agents tested in this study.
However, thel-oxa compound was effective against all staphylococcal isolates tested
at concentrations of 8.0 ug/ ml although it had no appreciable activity against
Streptococcusfaecalis isolates.
The in vitro activity of this new compound against Enterobacteriaceae, as well as
that of the other cephalosporins tested in the present study, was influenced by
inoculum size in both trypticase soy and Mueller-Hinton broth. This decrease in
activity of the 1-oxa compound was also observed against isolates of Pseudomonas
species in Mueller-Hinton but not in trypticase soy broth. The clinical significance, if
any, of these latter observations requires further study.
The results of the present study indicate that this new 1-oxa cephalosporin has a
broad spectrum of in vitro antibacterial activity which, except for staphylococcal
isolates, far exceeds the activity of older cephalosporins, including those agents-
particularly cefoxitin and cefamandole-which recently became available for general
clinical use. Furthermore, this new compound compares favorably with other
antimicrobial agents, including aminoglycosides and antipseudomonal penicillins,
against aerobic gram-negative enteric bacilli. Thus, this new antibiotic offers great
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promise as a broad-spectrum antibacterial agent and warrants properly controlled
future trials to determine its clinical efficacy in man.
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